{"disease":{"id":"cystic-fibrosis-general","name":"cystic fibrosis general"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"oligog-dry-powder-for-inhalation","indication_name":"Cystic Fibrosis (general)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OligoG Dry powder for inhalation","company_name":"AlgiPharma AS","drug_phase":"discontinued","molecular_target":"Bacterial biofilm matrix and adhesion mechanisms in cystic fibrosis airways","drug_class":"Anti-biofilm agent; inhaled oligosaccharide therapeutic","quality_score":null,"revenue":null,"mechanism":"OligoG is an inhaled oligosaccharide that disrupts bacterial biofilm formation and reduces pathogenic adherence in cystic fibrosis airways."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}